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Abstract
Micronutrients are indispensable for a variety of vital functions. Micronutrient deficiencies are a global problem
concerning two billion people. In most cases, deficiencies are treatable with supplementation of the elements in
lack. Drug-nutrient interactions can also lead to micronutrient reduce or depletion by various pathways.
Supplementation of the elements and long-term fortification programs for populations at risk can prevent and
restore the related deficiencies. Within the context of Predictive, Preventive, and Personalized Medicine, a multi-
professional network should be developed in order to identify, manage, and prevent drug-micronutrient
interactions that can potentially result to micronutrient deficiencies.
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What are micronutrients?
Micronutrients [1] is a term generally used to define
all essential vitamins and minerals mainly taken from
food sources and which are necessary for vital func-
tions [2, 3]. Micronutrients consist only of 0.01 % of
body mass [1]. Surprisingly, even if the amounts required
are very low, a lack of micronutrient can lead to severe,
non-ignorable health disorders, even threatening for life
[2]. Fortunately, most of these dysfunctions can disappear
after the administration of the elements in lack [3].
What about epidemiology?
Micronutrient deficiencies (MNDs) are a very common
condition. It is estimated that about two billion people
in the world suffer from MNDs [2]. Notably, this is not
a problem of developing countries exclusively [4]. Many
people in west societies are diagnosed with MNDs [4].
However, in these countries, MNDs often remain un-
diagnosed and are supposed to affect 1 in 3 persons [3].
Malnutrition is the major cause of MNDs [3], and it may
include low intake or malabsorption of micronutrients
owing to infection, inflammation, or a systematic disease
[2]. Pregnant women, children less than 5 years of age,
and elderly people are more likely to suffer from any
type of MNDs [2]. The most frequent deficiency is that
of iron [1], followed by vitamin A, folate, iodine, and
zinc deficiency [3]. In minors, vitamin and folate defi-
ciencies dominate across all age groups [4]. Appearance
of multiple MNDS is more common than that of sole
[2]. Table 1 describes selected micronutrient deficiencies
and their clinical manifestations and diagnosis.
But how micronutrient status can be determined?
Modern methods are currently used to count the amount
of a micronutrient in the body. The most accurate method
is metabolites biomarkers [1], which count micronutrient
levels using blood or urine samples [2]. The functional
intracellular analysis—within lymphocytes in blood sam-
ples or buccal mucosa cells—is a novel (part of -omics sci-
ence) reliable process of micronutrient testing [5–7].
How MNDs can be faced?
MNDs can be prevented massively by the fortification of
elements in lack in a country or region. Preventive pro-
grams are often applied to population at risk. The most
common example is the enrichment of table salt carried
forward by many governments. On the other hand,
population groups at risk may receive supplementation
according to guidelines. For instance, iron and folic acid
are prescribed to pregnant women [2].
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In modern societies, the increase of life-span leads to
multi-morbidity and inevitably to polypharmacy. Poly-
pharmacy added to inappropriate drug prescribing in-
creases the risk of drug-drug and drug-nutrient
interactions (DNIs) [8–10]. DNIs are not rare, with the
potential for over 300 remedies capable of interacting with
nutrient or food components [11]. MNDs can be the ad-
verse effect of these interactions, especially in elder and
chronically ill people with impaired nutritional status.
Drug-nutrient interactions
The term DNIs refers to physicochemical, physiological,
or pathophysiological relationships between a drug and a
nutrient [12] or, in a broad sense, between a drug and
multiple nutrients, food or components, or nutritional
status [13, 14]. DNIs can be classified in four types: type
I, ex vivo bio-inactivation; type II, decreased/increased
absorption; type III, decreased/increased effect; and type
IV, decreased/increased clearance [8, 9, 12].
A clinically significant drug-nutrient interaction is one
related to an impaired physiologic process (quantifiable
alteration of the kinetic and/or dynamic profile of a drug
or a nutrient), which may result to malnutrition, therapy
failure, adverse events, or even a life-threatening situ-
ation [8, 13]. Factors that may enhance the type and in-
tensity of DNIs include patient-related variables as age,
sex, comorbidities, nutritional status, and also drug- and
nutrient-associated factors as route of administration,
nutrient status, and pharmacological/toxicological pro-
file of the drug [8, 9, 13] (Fig. 1). Some of the effects that
commonly used drugs can have on micronutrient
homeostasis are described in the Table 2.
How DNIs can be addressed?
Physicians must coordinate with nutritionists, nurses,
and pharmacists in order to minimize DNIs and adverse
outcomes. Α comprehensive strategy can be planned,
based on their knowledge, experience, and skills. Aware-
ness of drug interactions with common dietary agents,
defined drug administration schedules, periodic review
of current drug therapy and dietary habits, proper edu-
cation of health-care providers, and computerized drug
interaction screening and warning software combined
with patient counseling are crucial steps of this innova-
tive approach [9, 10, 15].
Conclusion
MNDs can be the result of malnutrition or the adverse
outcome of common DNIs. In order to handle effectively
MNDs and DNIs, modern health-care services should be
governed by the principles of PPPM. PPPM uses ad-
vanced science technologies (genomic, proteomic, and
metabolomics biomarkers or bio-predictors) that allow
to determine individual predisposition to a particular ill-
ness and prevent clinically established dys-homeostasis,
by using personalized, preventive, and therapeutic strat-
egies [16, 17]. According to the National Institute of
Health (NIH) and other health authorities (European
Commission, US Food and Agriculture Association
(FDA), Centers for Disease Control and Prevention
(CDC)), PPPM constitutes a fundamental crucial axis of
development in the twenty-first century [16]. The pre-
dictive branch of PPPM includes the identification and
evaluation of new biomarkers/bio-predictors in subclin-
ical stages of the pathological process before the onset of
clinical manifestations [16, 17]. Pharmacogenomics and
nutrigenomics are new research fields that study gene-
drugs and gene-nutrient interactions, aiming for the de-
velopment of safe and effective drug-based therapies
and the selection of health-promoting nutrients for in-
dividuals [18]. Accumulating data about the molecular
mechanisms of DNIs will help us to generate a novel
Table 1 Selected micronutrients: role, signs, and symptoms of deficiencies and accurate diagnosis
Micronutrient Functions Symptoms and signs of deficiency Diagnosis
Iron Constituent of hemoglobin, carries out oxygen
transport, indispensable for cognitive functions
Anemia, endocrine and immune disorders,
↑ danger for maternal death
Newborns: ↓ birthweight, prematurity, perinatal
complications, physical and mental retardation




Vitamin A Participates in vision, immunization, reproduction,
growth
Sensitivity, infections, xerophthalmia and other
vision problems, blindness in children
↓ Serum retinol, ophthalmologic
examination
Iodine Constituent of thyroid hormone, CNS growth
in fetus and infant
Fetus: neurological and mental retardation
(permanent), cretinism
Adult: goiter, ↓ mental function, hypo/
hyperthyroidism
↓ Urine iodine
Folate Constituent of vitamin B, participates in DNA
synthesis, stability, and repair, disinclines mutations
Megalosblastic–macrocytic anemia
Fetus: neural tube defects
↓ Concentration in serum,
plasma, and erythrocytes
Zinc Activates enzymes involved in immunization,
necessary for fetus and children growth
↑ Morbidity and mortality of diarrhea,
respiratory infection, and malaria
No reliable biomarker due to ↓
bio-ability
For example, iron is an essential element for oxygen transportation, the red blood cells, and several enzymes’ production and important immune functions. Its
deficiency that affects millions lies hidden of the overall death rates, maternal hemorrhage, reduced mental, and physical performance. Reduced levels of blood
hemoglobin, serum ferritin, and low transferrin saturation confirm the diagnosis of iron deficiency
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Fig. 1 Drug-nutrient interactions: influencing factors, possible pathways, and potential effects on the micronutrient balance. Risk for drug-nutrient
interactions can be affected by many precipitating/influencing factors. These factors are related to individual characteristics (e.g., age, gender, medical
history, genetic profile), remedies (pharmacokinetics, pharmacodynamics), and micronutrients properties (nutrikinetics, nutridynamics). Frequently, DNIs
are bidirectional in their outcomes. Drugs can potentially influence the metabolism of micronutrients in multiple ways, from their intestinal absorption
to their cell bioavailability. Intermediate pathways include a wide range of alterations in physiological processes such as increase in gastrointestinal
motility (e.g., induced from metoclopramide, erythromycin, and cisapride) and thus limited absorption and increased nutrient loss. As a result, the
micronutrient balance is affected and elimination may occur in severe and prolonged DNI, when a drug impairs/inhibits micronutrient absorption or
metabolic functions
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drug-diet interactome map and thus to identify, predict,
and prevent possible unwanted interactions between
natural compounds and drugs [19]. Preventive measures
that include daily intake of micronutrients, accorded to
health authorities’ recommendations [20], supplemen-
tation of the elements in lack, and long-term fortifica-
tion programs for populations at risk can prevent and
restore the related deficiencies. In addition, high-risk
patients (elders, obese, critically ill, with chronic dis-
eases, with known genetic variants in drug transporters,
receptors, or enzymes) and individuals under high-risk
medication (antimicrobials, antiepileptics, warfarin,
drugs with narrow therapeutic index) should be tar-
geted for DNI monitoring [15, 16]. The physician’s
decision to screen for MNDs should be based on the
patient’s history, comorbidities, dietary habits, and life-
style. The aim of personalized medicine is the tailoring
of health-care services to the needs of the individual
patient and/or to the person-at-risk by the evaluation
of integrated health data (family history, medical data,
-omics profiles) [16, 17, 21]. Such holistic strategies can
be applied and support appropriate drug prescribing
and nutritional advices, in order to minimize DNIs and
MNDs, reduce health-care utilization and costs, and
enhance well-being.
Abbreviations
MNDs: micronutrient deficiencies; DNIs: drug-nutrient interactions;
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Table 2 Drug-micronutrient interactions: widely used categories and possible drug-induced pathways that lead to nutrient
depletions
Widely used drugs (category) Proposed mechanisms (Micro) nutrient depleted
Acid-suppressing and antacids ↓ Absorption H2 antagonists
Calcium, iron, zinc, folic acid, vitamin D, and vitamin B12
Proton-pump inhibitors (PPIs)







Folic acid, iron, vitamin A, vitamin D, B1 (thiamin),
B2 (riboflavin), B3, B6, B12, calcium, magnesium,
potassium, and vitamin K
Anti-hypertensives ↓ Cell availability
↑ Renal elimination
Angiotensin-converting enzyme inhibitors: zinc
Calcium channel blockers: potassium
Chlorthalidone, hydrochlorothiazide, zinc, potassium, B vitamins
Loop diuretics: calcium, magnesium, potassium, zinc,
vitamins B1 and B6
Hydralazine: vitamin B6 and coenzyme Q10
Beta-blockers: coenzyme Q10
Potassium-sparing diuretics: folic acid




Barbiturates: calcium, folic acid, vitamins D and K
Phenytoin: calcium, folic acid, vitamins B1, B2, and D
Carbamazepine: folic acid and vitamin D
Valproic acid: L-carnitine
Psychotherapeutic drugs Enzyme induction
↑ Metabolism
↓ Endogenous production
Selective serotonin reuptake inhibitors (SSRIs): folic acid
Benzodiazepines: melatonin, calcium
Tricyclic antidepressants, phenothiazines: coenzyme Q10
and vitamin B2
Haloperidol: coenzyme Q10
Cholesterol-lowering drugs: statins ↓ Cell availability
↓ Endogenous production
Coenzyme Q10, vitamin D
Digoxin ↑ Renal elimination Magnesium, potassium, calcium, phosphorus, vitamin B1
Oral hypoglycemics ↓ Absorption Metformin: vitamin B12
Oral contraceptives ↓ Absorption
Enzyme induction
Vitamin B6, folic acid, magnesium
Hormone replacement therapy (estrogens) ↓ Absorption
↑ Metabolism
↑ Excretion
Vitamin B6, folic acid, magnesium
Anti-inflammatory/analgesics ↓ Absorption
↓ Cell availability
Non-steroidal anti-inflammatory drugs: iron and folic acid
Salicylate: iron, folic acid, potassium, sodium, and vitamin C
For example, diuretics (anti-hypertensives) will possibly lead to a loss of micronutrients, especially of the water-soluble vitamins (vitamin B) and minerals (K, Mg,
Ca), due to renal hyper-excretion. Some antibiotics can reduce the vitamin K synthesis by intestinal bacteria. Metformin, after long-term therapy, is associated with
reduced vitamin B12 levels by decreasing the uptake of B12 via calcium-dependent ileal cell membrane receptors and thus affected absorption
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